Skip to main content
Anthem Biosciences Limited logo

Anthem Biosciences Limited — Investor Relations & Filings

Ticker · ANTHEM ISIN · INE0CZ201020 LEI · 335800FNA941U9NMD221 BSE.NS Professional, scientific and technical activities
Open in API
Filings indexed 84 across all filing types
Latest filing 2025-10-28 Regulatory Filings
Country IN India
Listing BSE.NS ANTHEM

About Anthem Biosciences Limited

https://anthembio.com/

Anthem Biosciences Limited is a comprehensive Contract Research and Manufacturing Services (CRAMS) organization providing integrated solutions across the drug discovery and development lifecycle. The company offers services including medicinal chemistry, process research, analytical validation, and large-scale commercial manufacturing. Its technical expertise spans synthetic organic chemistry, fermentation technology, molecular biology, and cell biology, enabling the production of both small molecules and biologics. Anthem serves global clients in the pharmaceutical, biopharmaceutical, and specialty chemical sectors. The organization features state-of-the-art research facilities and cGMP-compliant manufacturing units, facilitating a seamless transition from initial concept to market-ready products. Its commitment to intellectual property protection and rigorous quality management systems underpins its collaborative partnerships.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings Classification · 95% confidence The document is a notification addressed to stock exchanges regarding a violation of the company's Code of Conduct related to insider trading regulations under SEBI PIT Regulations. It mentions that the matter will be discussed in the Audit Committee meeting and that further disclosures will be made later. The document is short (1532 characters) and serves as an intimation or regulatory announcement rather than a detailed report or financial statement. It does not contain financial data, management discussion, or audit results. It is a regulatory compliance notification about insider trading violation, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-10-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is an announcement regarding the schedule of an earnings conference call to discuss the unaudited financial results for the quarter and half year ended September 30, 2025. It includes details about the call timing, dial-in options, and management participants. There are no actual financial statements or detailed financial analysis included in the text. The document serves to inform investors and the public about the upcoming earnings call rather than presenting the earnings results themselves. Therefore, it is best classified as a Call Transcript (CT) type document, specifically an announcement of an earnings call, which falls under the Call Transcript category.
2025-10-23 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2025-10-23 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges about an upcoming Board Meeting scheduled to approve unaudited financial results for the quarter and half year ended September 30, 2025. It references compliance with SEBI regulations and mentions the closure of the trading window for insiders. The document does not contain any financial data or results itself, nor does it include detailed financial statements or analysis. It is an announcement of a future event (Board Meeting) and the expected approval of financial results, not the results or report itself. The document length is short (1862 characters), and it serves as an intimation or notice rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-10-23 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2025. It is addressed to stock exchanges and certifies that details of securities dematerialized/rematerialized have been furnished as required. The document is a compliance certificate from the Registrar and Transfer Agent, not a financial report or announcement of financial results. It is short (3234 characters) and primarily serves as a regulatory attestation. Therefore, it fits the category of Regulatory Filings (RNS) as it is a regulatory compliance certificate rather than a financial report or announcement.
2025-10-06 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges about the closure of the trading window for insiders ahead of the board meeting to approve quarterly financial results. It references SEBI regulations on insider trading and informs about the trading restrictions period. There is no financial data, report content, or detailed analysis present. The document is an announcement related to compliance and trading restrictions, not a financial report or earnings release. Given the short length (1468 characters) and the nature of the content, this fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-09-29 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.